Back to Hou

Pitch competition returns to Houston with cybersecurity-focused event

Houston-based Hatch Pitch will host two competitions in spring of 2020 — one marks the return of the competition to the Bayou City. Photo courtesy of Hatch Pitch

For eight years, Greg Wright has been organizing a SXSW pitch competition in Austin for startups from around the world that are using technology to improve life. In 2020, Wright is bringing Houston-based Hatch Pitch back into the Bayou City — a goal he's had for a while — for a new cybersecurity-focused event.

"Many people know us as being associated with Austin and SXSW, but not many people know us as being based in Houston," Wright tells InnovationMap. "There's been a big push to bring Hatch back to Houston, and what we've been struggling with is finding the right vehicle."

After Hatch Pitch Summit returns to Austin for its ninth year on March 16, Cyber Hatch will be hosted by the annual Houston Cyber Summit on April 28. Applications for both competitions are open and available online.

"We are excited to bring Hatch Pitch to Houston for the first time since 2013," says Wright, founder of the competition, in a press release. "The gathering of all this expertise at Houston Cyber Summit is the perfect place to foster innovation. It's an opportunity to meet and exchange ideas between startups, investors, customers, partners, leaders and change-makers."

The Houston Cyber Summit, which is going into its fourth year, will introduce a new innovation track to the event, which attracts cybersecurity experts from across industries. The pitch competition will shine a spotlight on early-stage companies creating safety and security online.

"The Houston Cyber Summit annually brings together a highly qualified, trusted network of business, government and academic leaders from across the Greater Houston region and beyond," says Umesh Verma, founder of Houston Cyber Summit and CEO of BLUE LANCE. "Partnering with industry leader Hatch Pitch, adds a new and exciting dimension to the cybersecurity and privacy landscape of our region and creates a new set of high paying jobs."

For each of the two spring competitions, four finalists will be selecting from hundreds of applications from companies around the world. All eight finalists will have access to mentors before pitching at the live events where they will field questions from the panel of judges. Similar to years prior, the pitches will be live streamed.

Over the past near decade, Hatch Pitch finalists have gone on to raise over $360 million and seen 11 successful exits. Recently Houston-based Braincheck, which won the competition in 2016, raised an $8M series A round earlier this year.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News